On 23 May 2019, the Minister of Health excluded cannabidiol (CBD), one of the naturally occurring non-psychoactive cannabinoids found in the cannabis plant, from the Schedules for a period of 12 months, under restricted conditions.In Government Notice No. 586, Government Gazette No. 43347, issued on 22 May 2020, the Minister of Health has amended the Schedules as follows:
-
- Previous entries for cannabis, dronabinol, and tetrahydrocannabinol in Schedule 7 have been deleted.
- Cannabidiol (CBD) is listed in Schedule 4, except:
- in complementary medicines containing no more than 600 mg cannabidiol per sales pack, providing a maximum daily dose of 20 mg of cannabidiol, and making a general health enhancement, health maintenance or relief of minor symptoms (low-risk) claim; or
- processed products made from cannabis raw plant material intended for ingestion containing 0,0075 percent or less of cannabidiol where only the naturally occurring quantity of cannabinoids found in the source material are contained in the product.
Products that meet those listed conditions will instead be regulated as Schedule 0.
-
- (-)-transdelta-9-tetrahydrocannabinol (THC) is listed in Schedule 6, except –
- in raw plant material and processed products manufactured from such material, intended for industrial purposes and not for human or animal ingestion, containing 0,2 % percent or less of tetrahydrocannabinol;
- processed products made from cannabis containing 0,001 percent or less of tetrahydrocannabinol; or
- when raw plant material is cultivated, possessed, and consumed by an adult, in private for personal consumption.
- (-)-transdelta-9-tetrahydrocannabinol (THC) is listed in Schedule 6, except –
